Latest News

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

FDA clears lebrikizumab (EBGLYSS) every-8-week maintenance dosing for moderate to severe atopic dermatitis, reducing maintenance injections to as few as 6 per year.

This review of the latest dermatological studies includes insights on a mobile AI platform for skin disease prescreening, COVID-19 outcomes in PsO patients on biologics, i-PRF) and laser therapy for facial rejuvenation, and more.

Meta-analysis finds azithromycin pulse therapy matches doxycycline for moderate to severe acne, with fewer GI adverse events and less photosensitivity.

Dual-layer microneedle patch delivers fast itch relief and sustained methotrexate-zinc therapy, improving psoriasis inflammation, immune balance, and infection protection in mice.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

AI analysis of 187,016 menopausal women links hair loss severity to thyroid disease, gut symptoms, scalp inflammation, and genetics, supporting broader diagnostic workups beyond hormones.

As Epiduo goes OTC, offering once-daily adapalene+BPO for mild to moderate acne, Heather Woolery-Lloyd, MD, FAAD, gives advice on irritation, purging, and simplifying routines.